Mex3a Protects Against Atherosclerosis: Evidence From Mice and Humans
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES
1.
Álvarez-Varela A, Novellasdemunt L, Barriga FM, Hernando-Momblona X, Cañellas-Socias A, Cano-Crespo S, Sevillano M, Cortina C, Stork D, Morral C, et al. Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. Nat Cancer. 2022;3:1052–1070. doi: 10.1038/s43018-022-00402-0
2.
Domingo-Muelas A, Duart-Abadia P, Morante-Redolat JM, Jordán-Pla A, Belenguer G, Fabra-Beser J, Paniagua-Herranz L, Pérez-Villalba A, Álvarez-Varela A, Barriga FM, et al. Post-transcriptional control of a stemness signature by RNA-binding protein MEX3A regulates murine adult neurogenesis. Nat Commun. 2023;14:373. doi: 10.1038/s41467-023-36054-6
3.
Santovito D, Egea V, Bidzhekov K, Natarelli L, Mourão A, Blanchet X, Wichapong K, Aslani M, Brunßen C, Horckmans M, et al. Noncanonical inhibition of caspase-3 by a nuclear microRNA confers endothelial protection by autophagy in atherosclerosis. Sci Transl Med. 2020;12:eaaz2294. doi: 10.1126/scitranslmed.aaz2294
4.
Cimen I, Natarelli L, Kichi ZA, Henderson JM, Farina FM, Briem E, Aslani M, Megens RTA, Jansen Y, Mann-Fallenbuchel E, et al. Targeting a cell-specific microRNA repressor of CXCR4 ameliorates atherosclerosis in mice. Sci Transl Med. 2023;15:eadf3357. doi: 10.1126/scitranslmed.adf3357
5.
Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M, Hindy G, Zhou W, et al; Biobank Japan. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat Genet. 2022;54:1803–1815. doi: 10.1038/s41588-022-01233-6
Information & Authors
Information
Published In
Copyright
© 2024 American Heart Association, Inc.
History
Published online: 7 October 2024
Published in print: 8 October 2024
Keywords
Subjects
Authors
Disclosures
None.
Sources of Funding
This work was supported by the Deutsche Forschungsgemeinschaft SFB1123-A1/A10 to Drs Döring and Weber, SFB1123-Z1 to Dr Megens, SFB1123-B5 to Dr Santovito, 403584255-TRR 267-A2 to Drs Weber and Sattler, and TRR 267-B5 to Drs Chen and Schunkert; by the German Centre for Cardiovascular Research 81Z0600202 to Dr Weber and 81Z0600203 and 81X2600269 to Dr Santovito; by LMUexcellent, funded by the Federal Ministry of Education and Research and the Free State of Bavaria under the Excellence Strategy of the Federal Government and the Länder to Dr Santovito; and by the Federal Ministry of Education and Research in the framework of the Cluster4Future program (Cluster for Nucleic Acid Therapeutics Munich) to Drs Sattler and Weber.
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.